(Q50665296)

17 March 2018

title

Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome. (English)

1 reference

17 March 2018

author

James Nagarajah

5

1 reference

17 March 2018

author name string

Angela Köninger

1

1 reference

17 March 2018

L Koch

2

1 reference

17 March 2018

P Edimiris

3

1 reference

17 March 2018

A Enekwe

4

1 reference

17 March 2018

S Kasimir-Bauer

6

1 reference

17 March 2018

R Kimmig

7

1 reference

17 March 2018

T Strowitzki

8

1 reference

17 March 2018

B Schmidt

9

1 reference

17 March 2018

publication date

25 June 2014

1 reference

17 March 2018

Archives of Gynecology and Obstetrics

published in

1 reference

17 March 2018

volume

290

1 reference

17 March 2018

issue

5

1 reference

17 March 2018

page(s)

1023-1030

1 reference

17 March 2018

The prevalence and features of the polycystic ovary syndrome in an unselected population

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Polycystic ovaries and associated clinical and biochemical features in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Anti-Mullerian hormone confirms the novel classification of female functional androgenization including polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Assessment of insulin resistance in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Ultrasound assessment of the polycystic ovary: international consensus definitions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

Ordinal regression model and the linear regression model were superior to the logistic regression models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-014-3317-2

10.1007/S00404-014-3317-2

21 January 2018

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018